Development of sodium-dependent glucose co-transporter 2 inhibitors as potential anti-diabetic therapeutics

Current Topics in Medicinal Chemistry

Volumn 11, Issue 12, 2011, Pages 1476-1512

  Ho, Low Tone ^a,b   Kulkarni, Suvarn S ^c   Lee, Jinq Chyi ^d  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Dapagliflozin; Phlorizin; Sodium dependent glucose co transporter; Structure activity relationships; Type 2 diabetes mellitus

Indexed keywords

3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE; ACEROGENIN A; ACEROGENIN B; ACEROSIDE I; ACEROSIDE VII; ALSTIPHYLLANINE E; ALSTIPHYLLANINE F; ALSTIPHYLLANINE G; ALSTIPHYLLANINE H; ANTIDIABETIC AGENT; AVE 2268; BENZOFURAN DERIVATIVE; CANAGLIFLOZIN; DAPAGLIFLOZIN; DRUG METABOLITE; EGT 1442; EGT 1474; GLUCOSE; GLYCOSIDE; INDAZOLE DERIVATIVE; PHLORETIN; PHLORIZIN; REMOGLIFLOZIN ETABONATE; SERGLIFLOZIN; SERGLIFLOZIN A; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; T 1095A; UNCLASSIFIED DRUG; UNINDEXED DRUG; WAY 123783;

DIABETES MELLITUS; DIZZINESS; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG TREATMENT FAILURE; EXCESSIVE INSULIN SECRETION; FLATULENCE; GLUCOSE URINE LEVEL; GLUCOSURIA; HUMAN; HYPOGLYCEMIA; KIDNEY PROXIMAL TUBULE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SIDE EFFECT; STREPTOZOCIN DIABETES; STRUCTURE ACTIVITY RELATION; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 79959969142     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611795860915     Document Type: Review

References (82)

1. Bonadonna, R. C. Alterations of glucose metabolism in type 2 diabetes mellitus. An overview. Rev. Endocr. Metab. Disord., 2004, 5, 89-97.
2. +-glucose cotransporters: SLC5. Physiology, 2004, 19, 370-376.
3. +/glucose cotransporter. Nature, 1991, 350, 354-356.
4. +/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Nat. Genet., 1996, 12, 216-220.
5. +/glucose cotransporter gene SGLT1 in a patient with congenital glucose-galactose malabsorption: normal trafficking but inactivation of the mutant protein. Biochim. Biophys. Acta, 2001, 1536, 141-147.
6. Handlon, A. L. Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents. Expert Opin. Ther. Patents, 2005, 15, 1531-1540.
7. Washburn, W. N. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents. Expert Opin. Ther. Patents, 2009, 19, 1485-1499.
8. Ehrenkranz, J. R. L.; Lewis, N. G.; Kahn, C. R.; Roth, J. Phlorizin: a review. Diabetes Metab. Res. Rev., 2005, 21, 31-38.
9. +-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes, 1999, 48, 1794-1800.
10. Booth, A. N.; Jones, F. T.; DeEds, F. Metabolic and glucosuria studies on naringin and phloridzin. J. Biol. Chem., 1958, 233, 280-282.
11. Malathi, P.; Crane, R. K. Phlorizin hydrolase: a [-glucosidase of hamster intestinal brush border membrane. Biochim. Biophys. Acta, 1969, 173, 245-256.
12. +-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives based on a new concept. Chem. Pharm. Bull., 1996, 44, 1174-1180.
13. Diedrich, D. F. The comparative effects of some phlorizin analogs on the renal reabsorption of glucose. Biochim. Biophys. Acta, 1963, 71, 688-700.
14. Hase, J.; Kobashi, K.; Kobayashi, R. Studies on the inhibitors of the sodium-potassium activated adenosinetriphosphatase. I. Effect of phlorizin and related natural products. Chem. Pharm. Bull., 1973, 21, 1076-1079.
15. +-glucose cotransporter inhibitors as antidiabetic agents. II. Synthesis and structure-activity relationships of 4'-dehydroxyphlorizin derivatives. Chem. Pharm. Bull., 1998, 46, 22-33.
16. +-glucose cotransporter inhibitors as antidiabetic agents. III. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives modified at the OH groups of the glucose moiety. Chem. Pharm. Bull., 1998, 46, 1545-1555.
17. +-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives substituted on the B ring. J. Med. Chem., 1999, 42, 5311-5324.
18. Asano, T.; Anai, M.; Sakoda, H.; Fujishiro, M.; Ono, H.; Kurihara, H.; Uchijima, Y. SGLT as a therapeutic target. Drugs Fut., 2004, 29, 461-466.
19. +/glucose cotransporter as molecular targets of antidiabetic drugs. Curr. Med. Chem., 2004, 11, 2717-2724.
20. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am. J. Kidney Dis., 2009, 53, 875-883.
21. Dudash, J. Jr.; Zhang, X.; Zeck, R. E.; Johnson, S. G.; Cox, G. G.; Conway, B. R.; Rybczynski, P. J.; Demarest, K. T. Glycosylated dihydrochalcones as potent and selective sodium glucose cotransporter 2 (SGLT2) inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 5121-5125.
22. Fujikura, H.; Fushimi, N.; Nishimura, T.; Tatani, K.; Isaji, M. Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same. PCT Int. Appl., WO2002028872A1, April 11, 2002.
23. Katsuno, K.; Fujimori, Y.; Takemura, Y.; Hiratochi, M.; Itoh, F.; Komatsu, Y.; Fujikura, H.; Isaji, M. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J. Pharmacol. Exp. Ther., 2007, 320, 323-330.
24. Fujimori, Y.; Katsuno, K.; Ojima, K.; Nakashima, I.; Nakano, S.; Ishikawa-Takemura, Y.; Kusama, H.; Isaji, M. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur. J. Pharmacol., 2009, 609, 148-154.
25. y mice. Eur. J. Pharmacol., 2009, 618, 98-104.
26. Idris, I.; Donnelly, R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes. Metab., 2009, 11, 79-88.
27. Colca, J. R. Discontinued drugs in 2008: endocrine and metabolic. Expert Opin. Investig. Drugs, 2009, 18, 1243-1255.
28. Kees, K. L.; Caggiano, T. J.; Steiner, K. E.; Fitzgerald, J. J. Jr.; Kates, M. J.; Christos, T. E.; Kulishoff, J. M. Jr.; Moore, R. D.; McCaleb, M. L. Studies on new acidic azoles as glucose-lowering agents in obese, diabetic db/db mice. J. Med. Chem., 1995, 38, 617-628.
29. Kees, K. L.; Fitzgerald, J. J. Jr.; Steiner, K. E.; Mattes, J. F.; Mihan, B.; Tosi, T.; Mondoro, D.; McCaleb, M. L. New potent antihyperglycemic agents in db/db mice: synthesis and structureactivity relationship studies of (4-substituted benzyl)(trifluoromethyl)pyrazoles and-pyrazolones. J. Med. Chem., 1996, 39, 3920-3928.
30. +-glucose cotransporter (SGLT) inhibitors. Bioorg. Med. Chem. Lett., 2003, 13, 2269-2272.
31. Fujimori, Y.; Katsuno, K.; Nakashima, I.; Ishikawa-Takemura, Y.; Fujikura H.; Isaji, M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J. Pharmacol. Exp. Ther., 2008, 327, 268-276.
32. Kissei Pharmaceutical Co. Ltd. Discontinuation of the development of "Remogliflozin" by GlaxoSmithKline. News Release July 3, 2009.
33. Derdau, V.; Fey, T.; Atzrodt, J. Synthesis of isotopically labelled SGLT inhibitors and their metabolites. Tetrahedron, 2010, 66, 1472-1482.
34. Bickel, M.; Brummerhop, H.; Frick, W.; Glombik, H.; Herling, A. W.; Heuer, H. O.; Plettenburg, O.; Theis, S.; Werner, U.; Kramer, W. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittel-Forschung, 2008, 58, 574-580.
35. Zhang, X.; Urbanski, M.; Patel, M.; Zeck, R. E.; Cox, G. G.; Bian, H.; Conway, B. R.; Beavers, M. P.; Rybczynski, P. J.; Demarest, K. T. Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1. Bioorg. Med. Chem. Lett., 2005, 15, 5202-5206.
36. Zhang, X.; Urbanski, M.; Patel, M.; Cox, G. G.; Zeck, R. E.; Bian, H.; Conway, B. R.; Beavers, M. P.; Rybczynski, P. J.; Demarest, K. T. Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2. Bioorg. Med. Chem. Lett., 2006, 16, 1696-1701.
37. Link, J. T.; Sorensen, B. K. A method for preparing C-glycosides related to phlorizin. Tetrahedron Lett., 2000, 41, 9213-9217.
38. Ellsworth, B. A.; Meng, W.; Patel, M.; Girotra, R. N.; Wu, G.; Sher, P. M.; Hagan, D. L.; Obermeier, M. T.; Humphreys, W. G.; Robertson, J. G.; Wang, A.; Han, S.; Waldron, T. L.; Morgan, N. N.; Whaley, J. M.; Washburn, W. N. Aglycone exploration of Carylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2. Bioorg. Med. Chem. Lett., 2008, 18, 4770-4773.
39. Wang, Y.; Goekjian, P. G.; Ryckman, D. M.; Miller, W. H.; Babirad, S. A.; Kishi, Y. Preferred conformation of C-glycosides. 9. Conformational analysis of 1,4-linked carbon disaccharides. J. Org. Chem., 1992, 57, 482-489.
40. Kishi, Y. Preferred solution conformation of marine natural product palytoxin and of C-glycosides and their parent glycosides. Pure Appl. Chem., 1993, 65, 771-778.
41. Meng, W.; Ellsworth, B. A.; Nirschl, A. A.; McCann, P. J.; Patel, M.; Girotra, R. N.; Wu, G.; Sher, P. M.; Morrison, E. P.; Biller, S. A.; Zahler, R.; Deshpande, P. P.; Pullockaran, A.; Hagan, D. L.; Morgan, N.; Taylor, J. R.; Obermeier, M. T.; Humphreys, W. G.; Khanna, A.; Discenza, L.; Robertson, J. G.; Wang, A.; Han, S.; Wetterau, J. R.; Janovitz, E. B.; Flint, O. P.; Whaley, J. M.; Washburn, W. N. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 2008, 51, 1145-1149.
42. Han, S.; Hagan, D. L.; Taylor, J. R.; Xin, L.; Meng, W.; Biller, S. A.; Wetterau, J. R.; Washburn, W. N.; Whaley, J. M. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes, 2008, 57, 1723-1729.
43. Calado, J. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. IDrugs, 2009, 12, 785-798.
44. Katsiki, N.; Papanas, N.; Mikhailidis, D. P. Dapagliflozin: more than just another oral glucose-lowering agent? Expert Opin. Investig. Drugs, 2010, 19, 1581-1589.
45. Nomura, S.; Sakamaki, S.; Hongu, M.; Kawanishi, E.; Koga, Y.; Sakamoto, T.; Yamamoto, Y.; Ueta, K.; Kimata, H.; Nakayama, K.; Tsuda-Tsukimoto, M. Discovery of canagliflozin, a novel Cglucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J. Med. Chem., 2010, 53, 6355-6360.
46. Lansdell, M. I.; Burring, D. J.; Hepworth, D.; Strawbridge, M.; Graham, E.; Guyot, T.; Betson, M. S.; Hart, J. D. Design and synthesis of fluorescent SGLT2 inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 4944-4947.
47. Lee, J.; Lee, S.-H.; Seo, H. J.; Son, E.-J.; Lee, S. H.; Jung, M. E.; Lee, M.; Han, H.-K.; Kim, J.; Kang, J.; Lee, J. Novel C-aryl glucoside SGLT2 inhibitors as potential antodiabetic agents: 1,3,4-thiadiazolymethylphenyl glucoside congeners. Bioorg. Med. Chem., 2010, 18, 2178-2194.
48. Kim, M. J.; Lee, J.; Kang, S. Y.; Lee, S.-H.; Son, E.-J.; Jung, M. E.; Lee, S. H.; Song, K.-S.; Lee, M.; Han, H.-K.; Kim, J.; Lee, J. Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: pyridazinylmethylphenyl glucoside congeners. Bioorg. Med. Chem. Lett., 2010, 20, 3420-3425.
49. Lee, J.; Kim, J. Y.; Choi, J.; Lee, S.-H.; Kim, J.; Lee, J. Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 7046-7049.
50. Song, K.-S.; Lee, S. H.; Kim, M. J.; Seo, H. J.; Lee, J.; Lee, S.-H.; Jung, M. E.; Son, E.-J.; Lee, M.; Kim, J.; Lee, J. Synthesis and SAR of thiazolylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors. ACS Med. Chem. Lett., 2011, 2, 182-187.
51. Zhang W.; Welihinda, A.; Mechanic, J.; Ding, H.; Zhu, L.; Lu, Y.; Deng, Z.; Sheng, Z.; Lv, B.; Chen, Y.; Roberge, J. Y.; Seed, B.; Wang, Y.-X. EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA1c levels in db/db mice and prolongs the survival of stroke-prone rats. Pharmacol. Res., 2011, 63, 284-293.
52. Xu, B.; Feng, Y.; Lv, B.; Xu, G.; Zhang, L.; Du, J.; Peng, K.; Xu, M.; Dong, J.; Zhang, W.; Zhang, T.; Zhu, L.; Ding, H.; Sheng, Z.; Welihinda, A.; Seed, B.; Chen, Y. Ortho-substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg. Med. Chem., 2010, 18, 4422-4432.
53. Kang, S. Y.; Song, K.-S.; Lee, J.; Lee, S.-H.; Lee, J. Synthesis of pyridazine and thiazole analogs as SGLT2 inhibitors. Bioorg. Med. Chem., 2010, 18, 6069-6079.
54. Xu, B.; Lv, B.; Feng, Y.; Xu, G.; Du, J.; Welihinda, A.; Sheng, Z.; Seed, B.; Chen, Y. O-Spiro C-aryl glucosides as novel sodiumdependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 5632-5635.
55. Lv, B.; Xu, B.; Feng, Y.; Peng, K.; Xu, G.; Du, J.; Zhang, L.; Zhang, W.; Zhang, T.; Zhu, L.; Ding, H.; Sheng, Z.; Welihinda, A.; Seed, B.; Chen, Y. Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 6877-6881.
56. Lv, B.; Feng, Y.; Dong, J.; Xu, M.; Xu, B.; Zhang, W.; Sheng, Z.; Welihinda, A.; Seed, B.; Chen, Y. Conformationally constrained spiro C-arylglucosides as potent and selective renal sodiumdependent glucose co-transporter 2 (SGLT2) inhibitors. ChemMedChem, 2010, 5, 827-831.
57. Zhou, H.; Danger, D. P.; Dock, S. T.; Hawley, L.; Roller, S. G.; Smith, C. D.; Handlon, A. L. Synthesis and SAR of benzisothiazole-and indolizine-aa-D-glucopyranoside inhibitors of SGLT2. ACS Med. Chem. Lett., 2010, 1, 19-23.
58. Goodwin, N. C.; Mabon, R.; Harrison, B. A.; Shadoan, M. K.; Almstead, Z. Y.; Xie, Y.; Healy, J.; Buhring, L. M.; DaCosta, C. M.; Bardenhagen, J.; Mseeh, F.; Liu, Q.; Nouraldeen, A.; Wilson, A. G. E.; Kimball, S. D.; Powell, D. R.; Rawlins, D. B. Novel Lxylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. J. Med. Chem., 2009, 52, 6201-6204.
59. Robinson, R. P.; Mascitti, V.; Boustany-Kari, C. M.; Carr, C. L.; Foley, P. M.; Kimoto, E.; Leininger, M. T.; Lowe, A.; Klenotic, M. K.; MacDonald, J. I.; Maguire, R. J.; Masterson, V. M.; Maurer, T. S.; Miao, Z.; Patel, J. D.; Préville, C.; Reese, M. R.; She, L.; Steppan, C. M.; Thuma, B. A.; Zhu, T. C-Aryl glycoside inhibitors of SGLT2: exploration of sugar modifications including C-5 spirocyclization. Bioorg. Med. Chem. Lett., 2010, 20, 1569-1572.
60. Kakinuma, H.; Oi, T.; Hashimoto-Tsuchiya, Y.; Arai, M.; Kawakita, Y.; Fukasawa, Y.; Iida, I.; Hagima, N.; Takeuchi, H.; Chino, Y.; Asami, J.; Okumura-Kitajima, L.; Io, F.; Yamamoto, D.; Miyata, N.; Takahashi, T.; Uchida, S.; Yamamoto, K. (1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for type 2 diabetes treatment. J. Med. Chem., 2010, 53, 3247-3261.
61. Kajimoto, T.; Liu, K. K.-C.; Pederson, R. L.; Zhong, Z.; Ichikawa, Y.; Porco, J. A. Jr.; Wong, C.-H. Enzyme-catalyzed aldol condensation for asymmetric synthesis of azasugar: synthesis, evaluation, and modeling of glycosidase inhibitors. J. Am. Chem. Soc., 1991, 113, 6187-6196.
62. Mascitti, V.; Préville, C. Stereoselective synthesis of a dioxabicyclo[3.2.1]octane SGLT2 inhibitor. Org. Lett., 2010, 12, 2940-2943.
63. Park, E.-J.; Kong, Y.; Lee, J. S.; Lee, S.-H.; Lee, J. Exploration of SAR regarding glucose moiety in novel C-aryl glucoside inhibitors of SGLT2. Bioorg. Med. Chem. Lett., 2011, 21, 742-746.
64. Gao, Y. L.; Zhao, G. L.; Liu, W.; Shao, H.; Wang, Y. L.; Xu, W. R.; Tang, L. D.; Wang, J. W. Design, synthesis and in vivo hypoglycemic activity of tetrazole-bearing N-glycosides as SGLT2 inhibitors. Indian J. Chem., 2010, 49B, 1499-1508.
65. Yao, C.-H.; Song, J.-S.; Chen, C.-T.; Yeh, T.-K.; Hung, M.-S.; Chang, C.-C.; Liu, Y.-W.; Yuan, M.-C.; Hsieh, C.-J.; Huang, C.-Y.; Wang, M.-H.; Chiu, C.-H.; Hsieh, T.-C.; Wu, S.-H.; Hsiao, W.-C.; Chu, K.-F.; Tsai, C.-H.; Chao, Y.-S.; Lee, J.-C. Discovery of novel N----D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes. J. Med. Chem., 2011, 54, 166-178.
66. Castaneda, F.; Burse, A.; Boland, W.; Kinne, R. K-H. Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes. Int. J. Med. Sci., 2007, 4, 131-139.
67. Gao, Y.; Zhao, G.; Liu, W.; Wang, Y.; Xu, W.; Wang, J. Thiadiazole-based thioglycosides as sodium-glucose co-transporter 2 (SGLT2) inhibitors. Chin. J. Chem., 2010, 28, 605-612.
68. Wang, Z.; Zhao, G.; Liu, W.; Wang, Y.; Shao, H.; Xu, W.; Tian, L. Design, synthesis and anti-diabetic activity of thiadiazole-based thioglycosides as SGLT2 inhibitors. Chin. J. Org. Chem., 2010, 30, 849-859.
69. +-Glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg. Med. Chem., 2007, 15, 3445-3449.
70. +-glucose cotransporter (SGLT) inhibitors from Acer nikoense. Bioorg. Med. Chem. Lett., 2010, 20, 1070-1074.
71. Arai, H.; Hirasawa Y.; Rahman, A.; Kusumawati, I.; Zaini, N. C.; Sato, S.; Aoyama C.; Takeo, J.; Morita, H. Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg. Med. Chem., 2010, 18, 2152-2158.
72. Wu, J.-S.; Peng, Y.-H.; Wu, J.-M.; Hsieh, C.-J.; Wu, S.-H.; Coumar, M. S.; Song, J.-S.; Lee, J.-C.; Tsai, C.-H.; Chen, C.-T.; Liu, Y.-W.; Chao, Y.-S.; Wu, S.-Y. Discovery of non-glycoside sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors by ligand-based virtual screening. J. Med. Chem., 2010, 53, 8770-8774.
73. Bailey, C. J. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol. Sci., 2011, 32, 63-71.
74. Komoroski, B.; Vachharajani, N.; Boulton, D. W.; Kornhauser, D.; Geraldes, M.; Li, L.; Pfister, M. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin. Pharmacol. Ther., 2009, 85, 520-526.
75. Komoroski, B.; Vachharajani, N.; Feng, Y.; Li, L.; Kornhauser, D.; Pfister, M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther., 2009, 85, 513-519.
76. Kasichayanula, S.; Liu, X.; Shyu, W. C.; Zhang, W.; Pfister, M.; Griffen, S. C.; Li, T.; LaCreta, F. P.; Boulton, D. W. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes. Metab., 2011, 13, 47-54.
77. Kasichayanula, S.; Chang, M.; Hasegawa, M.; Liu, X.; Yamahira, N.; LaCreta, F. P.; Imai, Y.; Boulton, D. W. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporer 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes. Metab., 2011, 13, 357-365.
78. List, J. F.; Woo, V.; Morales, E.; Tang, W.; Fiedorek, F. T. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care, 2009, 32, 650-657.
79. Ferrannini, E.; Ramos, S. J.; Salsali, A.; Tang, W.; List, J. F. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care, 2010, 33, 2217-2224.
80. Zhang, L.; Feng, Y.; List, J.; Kasichayanula, S.; Pfister, M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes. Metab., 2010, 12, 510-516.
81. Wilding, J. P.; Norwood, P.; T'joen, C.; Bastein, A.; List, J. F.; Fiedorek, F. T. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care, 2009, 32, 1656-1662.
82. Bailey, C. J.; Gross, J. L.; Pieters, A.; Bastein, A.; List, J. F. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo-controlled trial. Lancet, 2010, 375, 2223-2233.